# Credit Agricole Entreprises

> Credit Agricole Entreprises is a VC fund backing Medical and Wireless. See 6 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Chartres, France
- Total investments: 6
- Last investment: Sep 2021
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/7467
- X (Twitter): http://twitter.com/CreditAgricole
- Website: http://www.credit-agricole.fr/entreprise
- Facebook: http://www.facebook.com/CreditAgricole

Credit Agricole Entreprises is an investment firm focused on the agricultural sector.

## Contacts

5 contacts available for Credit Agricole Entreprises. Shizune tracks 1 team members at Credit Agricole Entreprises. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/credit-agricole-entreprises?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 33% |
| Wireless | 2 | 33% |
| Biotechnology | 2 | 33% |
| CAD | 1 | 17% |
| Gaming | 1 | 17% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 2 | 33% |
| Series A | 1 | 17% |
| Series B | 1 | 17% |
| Series D | 1 | 17% |
| Private Equity | 1 | 17% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Damien Ailleret | Directeur Entreprises | 1 | https://shizune.co/investors/profile/damien-ailleret |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Amolyt Pharma | Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. | $80M | Series B | Sep 16, 2021 |  |
| 3DRudder | 3DRudder develops and markets a device that enables its users to play video games in virtual reality and 3D environments. The device is controlled by the feet and enables players to move through virtual reality and 3D platforms. 3DRudder’s foot-powered motion controller is able to provide remote control solutions for industrial purposes and create3D models. 3DRudder is headquartered in Marseille, France. And it was founded in October 2014 by Valerio Bonora. | $1.5M | Series A | Sep 30, 2016 |  |
| HIKOB | In a world with limited resources and confined space, the understanding and exploitation of our physical assets, capital goods, infrastructures, industrial equipments and machinery, is a crucial challenge for years to come. During the life cycle of these assets, the acquisition of data is essential and is a key factor in the process of: -Knowledge & understanding: It consists in a better understanding to create and innovate. - Exploitation & maintenance: It consists in a better use to reduce costs and make it last. However to be useful and data has to be captured at the source on these assets in their real life conditions and in their real context of use: - Outdoor environment - Large natural spaces - Harsh or regulated environments - Mobility contexts HIKOB’s mission is to develop and provide wireless autonomous multi-points data acquisition system to capture information on the field and learn from reality, in all contexts and conditions. Provided as a fully integrated hardware and software platform, HIKOB systems collect complex data and support advanced data processing algorithms. Quick and easy to install, long lasting, HIKOB systems enable not only the multiplication of measurement points but also deployments in all contexts and all type of fields, while avoiding the installation and maintenance costs of traditional wired systems. HIKOB technologies are a key enabler and a result booster for businesses in their development and innovation process as well as for operations and maintenance. | $1.5M |  | Apr 06, 2016 |  |
| Amolyt Pharma | Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. | $2M |  | Mar 17, 2015 |  |
| Cortus SAS | Cortus (a founding platinum member of the RISC-V Foundation) works with its customers to provide intelligent processing and system on chip solutions according to their requirements. We draw on a wide range of in house IPs including analog circuits as well as both RISC-V and proprietary ISA 32 and 64 bit processors, system level IP, interconnect IP,coherent caches, compilers, RTOSes and embedded software which we use to provide complete HW, SW and system level solutions which give our customers significative competitive advantages in all kinds of application domain from Bank Cards to Automotive SoCs (sensor interfaces, image processing etc) to Space (Rad Hard for satellites).If you need something different to make you better than your competitors, then talk to us. We may well be able to come up with exactly what you need.We also have developed complete SoCs for different customers including one for IoT. This particular solution includes a medium range RF transceiver along with a powerful micro-controller, AES in hardware, as well as a a large embedded flash memory. Everything needed for a secure, low cost, low power (up to 10 years battery life from a button cell) solution suitable for a wide range of IoT applications in smart buildings including ESL in supermarkets and in car parks.Cortus IPs have been used in more than 6 billion devices. |  | Private Equity | Sep 22, 2011 |  |
| Diatos | Diatos is a biopharmaceutical company founded in 1999 and headquartered in Paris, France with two subsidiaries in Leuven, Belgium and in the San Francisco Bay Area, USA.Diatos is focused on the research, development and marketing of new versions of existing anti-cancer chemotherapeutic drugs with enhanced tumor targeting or improvedbiodistribution. Diatos has built its portfolio of drugs and drug candidates through a strategy of license acquisitions as well as an internal research and development activity based on its prodrug technologies, Vectocell® and Tumor-Selective Prodrug (TSP). | $12.8M | Series D | Jul 03, 2007 |  |

6 of 6 investments shown.

## Co-investors
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 2 deals together
- [Rhone-Alpes Creation](https://shizune.co/investors/profile/rhone-alpes-creation) — VC Fund, 2 deals together
- [Sham Innovation Santé](https://shizune.co/investors/profile/sham-innovation-sant%C3%A9) — VC Fund, 2 deals together
- [Alps Capital innovation](https://shizune.co/investors/profile/alps-capital-innovation) — VC Fund, 1 deal together
- [ATEM Capital Fund LP](https://shizune.co/investors/profile/atem-capital) — VC Fund, 1 deal together
- [Biotech Fund Flanders](https://shizune.co/investors/profile/biotech-fund-flanders) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund
- [Andreessen Horowitz](https://shizune.co/investors/profile/andreessen-horowitz) — VC Fund

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

### Similar country
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund

## Featured in investor lists
- [Infrastructure Investors in Europe](https://shizune.co/investors/infrastructure-investors-europe)
- [Infrastructure Investors in France](https://shizune.co/investors/infrastructure-investors-france)

## FAQ

### What does Credit Agricole Entreprises invest in?

Credit Agricole Entreprises invests primarily in Medical, Wireless and Biotechnology startups, most often at Funding Round and Series A stage. Most of the 6 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Credit Agricole Entreprises?

Public channels for Credit Agricole Entreprises include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Credit Agricole Entreprises?

The team at Credit Agricole Entreprises includes Damien Ailleret (Directeur Entreprises). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co